Jan ter Meulen - Publications, H-index & Citations

Jan ter Meulen

obsidian therapeutics

46H指数

162论文数

7.9K被引数

收录论文 57

发表时间

IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15 IL-2非依赖性扩增、持久性及抗肿瘤活性，在表达可调控膜结合型IL-15的肿瘤浸润淋巴细胞中

Molecular Therapy

IF12

2025-04-24

PREAI

Rachel A. Burga; Bulent Arman Aksoy; Zheng Ao; Jeremy H. Tchaicha; Dhruv K. Sethi; Alonso Villasmil Ocando; Gauri S. Kulkarni; Scott Lajoie; Kyle D. Pedro; Jack Ryan Tremblay; Meghan Langley; Benjamin Primack; Violet A. Young; Theresa Ross; Mithun Khattar; Dexue Sun; Dan Jun Li; Shyam Subramanian; Michelle Ols; Jan ter Meulen

Carbonic anhydrase 2-derived drug-responsive domain regulates membrane-bound cytokine expression and function in engineered T cells

COMMUNICATIONS BIOLOGY

IF5.1

2025-01-09

OAAI

Inniss, Mara C.; Smith, Sean G.; Li, Dan Jun; Primack, Benjamin; Sun, Dexue; Olinger, Grace Y.; Sheahan, Kerri-Lynn; Ross, Theresa; Langley, Meghan; Young, Violet; Alvarado, Andres; Davoodi, Shabnam; Geng, Jiefei; Schebesta, Michael; Ols, Michelle L.; Tchaicha, Jeremy; ter Meulen, Jan; Sethi, Dhruv K.

Tumor-infiltrating lymphocytes (TIL) engineered with membrane-bound IL15 (cytoTIL15 cells) exhibit pharmacologically regulatable signal transduction in cis and trans

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Burga, Rachel; Kulkarni, Gauri; Ao, Zheng; Sethi, Dhruv K.; ter Meulen, Jan; Ols, Michelle

Tumor-infiltrating lymphocytes (TIL) engineered with regulatable membrane-bound IL15 (mbIL15) and LIGHT (TNFSF14) show enhanced efficacy in fibroblast-containing cold tumors

CANCER RESEARCH

IF16.6

2024-04-05

PREAI

Koscso, Balazs; Ao, Zheng; Passaro, Carmela; Shah, Nirzari; Ly, Ngoc; Timpug, Patricia; Aksoy, Bulent A.; Sun, Dexue; Li, Dan Jun; Sheahan, Kerri-Lynn; Young, Violet; Ross, Theresa; Primack, Benjamin; Langley, Meghan; Tchaicha, Jeremy; Sethi, Dhruv K.; ter Meulen, Jan; Ols, Michelle

IL15-engineered tumor infiltrating lymphocytes (cytoTIL15™) exhibit activity against autologous tumor cells from multiple solid tumor indications without IL2

CANCER RESEARCH

IF16.6

2023-04-14

PREAI

Pedro, Kyle D.; Burga, Rachel; Ocando, Alonso Villasmil; Langley, Meghan; Kulkarni, Gauri; Ao, Zheng; Primack, Benjamin; Ross, Theresa; Young, Violet; Tchaicha, Jeremy; Ols, Michelle; Ter Meulen, Jan

Engineering tumor infiltrating lymphocytes from sarcoma and colorectal tumors with membrane bound IL-15 for IL-2 independent expansion and enhanced cytotoxicity against autologous tumor cell lines

CANCER RESEARCH

IF16.6

2023-04-14

PREAI

Ao, Zheng; Passaro, Carmela; Aksoy, Bulent A.; Koscso, Balazs; Burga, Rachel; Pedro, Kyle; Ly, Natasha; Shah, Nirzari; Ocando, Alonso V.; Kulkarni, Gauri; Timpug, Trisha; Pollack, Seth M.; ter Meulen, Jan; Ols, Michelle L.

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice

SCIENTIFIC REPORTS

IF3.9

2023-03-21

OAAI

Horvath, Dennis; Temperton, Nigel; Mayora-Neto, Martin; Da Costa, Kelly; Cantoni, Diego; Horlacher, Reinhold; Guenther, Armin; Brosig, Alexander; Morath, Jenny; Jakobs, Barbara; Groettrup, Marcus; Hoschuetzky, Heinz; Rohayem, Jacques; ter Meulen, Jan

cytoTIL15: A novel TIL therapy for melanoma with superior potency and enhanced persistence without IL2 to improve safety & efficacy and expand patient eligibility

ANNALS OF ONCOLOGY

IF65.4

2021-09-01

OAAI

Khattar, M.; Burga, R.; Pedro, K.; Foley, C.; Lajoie, S.; Ocando, A. V.; Tremblay, J.; Thornton, D.; Tam, S.; Nabulsi, F.; Vallaster, C.; Saha, S.; Wilmes, G.; Helmlinger, G.; Tchaicha, J.; Sethi, D.; Ols, M.; Vanasse, G.; Subramanian, S.; ter Meulen, J.

A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

ONCOIMMUNOLOGY

IF6.3

2020-11-19

OAAI

Somaiah, Neeta; Chawla, Sant P.; Block, Matthew S.; Morris, John C.; Do, Khanh; Kim, Joseph W.; Druta, Mihaela; Sankhala, Kamalesh K.; Hwu, Patrick; Jones, Robin L.; Gnjatic, Sacha; Kim-Schulze, Seunghee; Tuballes, Kevin; Yishak, Mahlet; Lu, Hailing; Yakovich, Adam; Ter Meulen, Jan; Chen, Michael; Kenney, Richard T.; Bohac, Chet; Pollack, Seth M.

Intratumoral immune activation with TLR4 agonist synergizes with effector T cells to eradicate established murine tumors

NPJ VACCINES

IF6.5

2020-06-16

OAAI

Albershardt, Tina C.; Leleux, Jardin; Parsons, Andrea J.; Krull, Jordan E.; Berglund, Peter; ter Meulen, Jan

The TLR4 agonist G100 enhances rituximab-mediated ADCC in vitro and has synergistic anti-tumor effects with anti-CD20 mAb in vivo

CANCER RESEARCH

IF16.6

2019-07-01

PREAI

Lu, Hailing; Betancur, Alec; ter Meulen, Jan

Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope

CELL REPORTS

IF6.9

2019-01-01

OAAI

Lu, Xishan; Xiao, Haixia; Li, Shihua; Pang, Xuefei; Song, Jian; Liu, Sheng; Cheng, Huijun; Li, Yan; Wang, Xiangxi; Huang, Chaobin; Guo, Tianling; ter Meulen, Jan; Daffis, Stephane; Yan, Jinghua; Dai, Lianpan; Rao, Zihe; Klenk, Hans-Dieter; Qi, Jianxun; Shi, Yi; Gao, George F.

Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial

NPJ VACCINES

IF6.5

2018-01-23

OAAI

Pillet, Stephane; Aubin, Eric; Trepanier, Sonia; Poulin, Jean-Francois; Yassine-Diab, Bader; ter Meulen, Jan; Ward, Brian J.; Landry, Nathalie

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient

JOURNAL OF IMMUNOTHERAPY

IF2.9

2017-10-01

OAAI

Pollack, Seth M.; Lu, Hailing; Gnjatic, Sacha; Somaiah, Neeta; O'Malley, Ryan B.; Jones, Robin L.; Hsu, Frank J.; ter Meulen, Jan

ZVex® lentiviral vector strongly activates pro-inflammatory, antigen processing, and anti-viral defense response pathways in monocyte-derived dendritic cells

CANCER RESEARCH

IF16.6

2017-07-01

PREAI

Bajaj, Anshika; Ngo, Lisa Y.; Berglund, Peter; ter Meulen, Jan

Large established B16 tumors in mice are eradicated by ZVex® (dendritic cell-targeting lentiviral vector) and G100 (TLR4 agonist) combination immunotherapy through increasing tumor-infiltrating effector T cells and inducing antigen spreading

CANCER RESEARCH

IF16.6

2017-07-01

PREAI

Albershardt, Tina C.; Parsons, Andrea J.; Leleux, Jardin; Berglund, Peter; ter Meulen, Jan

Immune Design

HUMAN VACCINES & IMMUNOTHERAPEUTICS

IF3.5

2017-01-04

OAAI

ter Meulen, Jan; Brady, Stephen R.

An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2016-07-24

OAAI

Johnson, Reed F.; Kurup, Drishya; Hagen, Katie R.; Fisher, Christine; Keshwara, Rohan; Papaneri, Amy; Perry, Donna L.; Cooper, Kurt; Jahrling, Peter B.; Wang, Jonathan T.; ter Meulen, Jan; Wirblich, Christoph; Schnell, Matthias J.

Intratumoral injection of G100 (TLR4 agonist glycopyranosyl lipid A) modulates tumor microenvironment and induces CD8 T cell-dependent, systemic anti-tumor immunity

CANCER RESEARCH

IF16.6

2016-07-15

PREAI

Lu, Hailing; Hewitt, Jessica; ter Meulen, Jan

Intratumoral expression of IL-12 from a dendritic cell-targeting chimeric lentiviral vector from the ZVex plafform cures established tumors in multiple models and induces systemic anti-tumor responses

CANCER RESEARCH

IF16.6

2016-07-15

PREAI

Albershardt, Tina C.; Bajaj, Anshika; Archer, Jacob F.; Reeves, Rebecca S.; Parsons, Andrea J.; Ngo, Lisa Y.; ter Meulen, Jan; Berglund, Peter

研究方向